Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Jan 12, 2024 3:56pm

102 Views

Post# 35824308

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

More nonsense Quenty.

It's hardly misleading that we're phase 3 ready. We have met the standards for moving to Phase 3 and have just added a board member who specializes in taking Biotechs to and through Phase 3. Look who's been added to our Board and Advisors recently. This company has never been here before with this board in place. You'll have to let the past go.

Your desperate need to beat us down is clear and your reasoning is garbage.

<< Previous

Bullboard Posts

Next >>

Ivanhoe Mines initiates Phase 3 concentrator construction